

Factsheet

Marketing Material

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C

A sub fund of Xtrackers (IE) Plc

This factsheet is as of april 30, 2026 unless otherwise specified

At a Glance

- Provides diversified exposure to global equities
- Provides exposure to up to 100 stocks which are exposed to themes linked to genomic healthcare innovation
- ESG Screened methodology

Fund information

ISIN	IE000KD0BZ68
Share class currency	USD
Fund Currency	USD
Fund launch date	12/07/2022
Share class launch date	12/07/2022
Domicile	Ireland
Portfolio Methodology	Direct Replication (physically)
Custodian	State Street Custodial Services (Ireland) Limited
All-in fee ¹	0.30% p.a.
Income treatment	Capitalizing
NAV per Share	USD 32.13
Total Fund Assets	USD 8.59 Million
Total Shares Outstanding	267,263
Reporting Fund	Yes
Transparency according to Regulation (EU) 2019/2088	Article 8. Financial product integrates ESG characteristics

¹ A Glossary can be found on etf.dws.com.

Performance

» [Historical Performance \(online\)](#)

Listing and trading information

Exchange	Bloomberg Ticker	Reuters RIC	Trading Currency
Borsa Italiana	XGEN IM	XGEN.MI	EUR
London Stock Exchange	XGEN LN	XGEN.L	USD
London Stock Exchange	XGES LN	XGES.L	GBP
XETRA	XGEN GY	XGEN.DE	EUR

Key Risks

The value of your investment may go down as well as up and past performance does not predict future returns. Investor capital may be at risk up to a total loss. The value of an investment in shares will depend on a number of factors including, but not limited to, market and economic conditions, sector, geographical region and political events.

The Fund has a focus on a single or narrow range of industry, sector or types of companies and performance may not reflect a rise in broader markets.

The Fund is exposed to less economically developed economies (known as emerging markets) which involve greater risks than well developed economies. Political unrest and economic downturn may be more likely and will affect the value of your investment.

The Fund invests in small and mid-capitalisation companies, which potentially involves greater risks compared to investing in large capitalisation companies. The shares may have less liquidity and could experience more price swings (or volatility) which could adversely affect the value of your investment.

The Fund is exposed to the currency markets which may be highly volatile. Large price swings can occur in such markets within very short periods and may result in your investment suffering a loss.

The following is applicable if you subscribe for or settle shares in a different currency than the fund or share-class currency: Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies.

Index key facts

Index name	MSCI ACWI IMI Genomic Innovation Select Screened 100 Index
Index provider	MSCI Inc.
Bloomberg symbol	NU738645
Index base currency	USD
Number of Index constituents	97

Source: Index Provider

Reference Index key features

The MSCI ACWI IMI GENOMIC INNOV SELCT SCRND 100 aims to reflect the performance of the following market:

- Large, medium, and small-capitalisation companies across developed and emerging markets globally
- Securities must meet a certain relevance score threshold with the theme of technological innovation in the genomic healthcare sector to be eligible for inclusion
- Securities issued by entities failing to meet the following ESG standards, amongst others, are excluded: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global Compact principles
- Reviewed semi-annually and rebalanced at least quarterly

Additional information on the index, selection and weighting methodology is available at <https://www.msci.com/>.

Top 10 ETF constituents

Issuer	ISIN	Weight
NATERA INC	US6323071042	4.93%
ELI LILLY	US5324571083	4.56%
VERTEX PHARMACEUTICALS INC	US92532F1003	4.53%
LONZA GROUP AG	CH0013841017	4.47%
ILLUMINA INC	US4523271090	4.42%
DANAHER CORP	US2358511028	4.39%
AGILENT TECHNOLOGIES INC	US00846U1016	4.35%
ROCHE PS PAR AG	CH1499059983	4.12%
ABBOTT LABORATORIES	US0028241000	4.09%
INSMED INC	US4576693075	4.03%

Source: DWS

About us

Xtrackers, DWS's global platform for Exchange Traded Funds (ETF) and Exchange-traded commodity (ETC) solutions, began in 2007 with ETFs tracking major leading indices.

Today, with approximately EUR 308 billion¹ in UCITS assets under management, Xtrackers is amongst the largest and most established ETF providers in Europe².

With around 300 products, Xtrackers offers a comprehensive range of efficient, high-quality ETFs and ETCs across all major asset classes, including equities, fixed income and commodities.

The product offering continues to grow. Xtrackers products are currently listed on eleven exchanges worldwide.

¹ Source: DWS, April 30, 2026

² Source: Deutsche Bank ETF Research

Further information on Xtrackers

DWS Investments UK Limited
21 Moorfields
London EC2Y 9DB
United Kingdom

E-Mail: Xtrackers@dws.com
Website: www.Xtrackers.com

Additional information

A Glossary of Terms is available at Xtrackers.com.

Disclaimer

This document is intended for information purposes only and does not create any legally binding obligations on the part of DWS Group GmbH & Co. KGaA and/or its affiliates (DWS).

This document has been prepared without consideration of the investment needs, objectives or financial circumstances of any investor. Without limitation, this document does not constitute an offer, an invitation to offer or a recommendation to enter into any transaction.

Before making an investment decision, investors need to consider, with or without the assistance of an investment adviser, whether the investments and strategies described or provided by DWS are appropriate in light of their particular investment needs, objectives and financial circumstances.

Information in this document has been obtained or derived from sources believed to be reliable and current. However, accuracy or completeness of the sources cannot be guaranteed.

This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions.

Xtrackers (IE) plc is an undertaking for collective investment in transferable securities (UCITS) in accordance with the applicable laws and regulations and set up as open-ended investment company with variable capital and segregated liability amongst its respective compartments.

Investors must buy and must usually sell shares in Xtrackers UCITS ETFs on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying shares and may receive less than the current net asset value when selling them. Before making any investment decision, investors should refer to the Risk Factors in the Prospectus and Key Investor Information Document.

Tax treatment of the Xtrackers UCITS ETFs depends on the individual circumstances of each investor.

Xtrackers (IE) plc is incorporated in Ireland with registered number 393802 and has its registered office at 78 Sir John Rogerson's Quay, Dublin 2, Ireland. DWS Investment S.A. acts as the management company of Xtrackers (IE) plc. The Investment Company may decide to terminate the arrangements made for the marketing of this fund

Any investment decision in relation to a fund should be based solely on the latest version of the prospectus, the audited annual and, if more recent, un-audited semi-annual reports and the Key Investor Information Document (KIID), all of which are available in English upon request to DWS Investment

S.A., 2, Boulevard Konrad Adenauer, L-1115 Luxembourg or on www.Xtrackers.com. A summary of investor rights is available at www.etf.dws.com under "About Us – How to Complain?".

PAST PERFORMANCE DOES NOT PREDICT FUTURE RETURNS.

This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Further information in relation to the UK sustainability labelling and disclosure requirements can be found on the UK FCA's website.

© DWS Investments UK Limited, 2026. Authorised and regulated by the Financial Conduct Authority.

Index Disclaimer

The MSCI Genomic Healthcare Innovation UCITS ETF ARE NOT SPONSORED, ENDORSED, SOLD OR PROMOTED BY MSCI INC. ("MSCI") OR ANY OF ITS AFFILIATES, INFORMATION PROVIDERS OR OTHER THIRD PARTY INVOLVED IN, OR RELATED TO, COMPILING, COMPUTING OR CREATING ANY MSCI INDEX (COLLECTIVELY, THE "MSCI PARTIES"). THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES ARE SERVICE MARK(S) OF MSCI OR ITS AFFILIATES AND HAVE BEEN LICENSED FOR USE FOR CERTAIN PURPOSES BY PRINCIPAL. NONE OF THE MSCI PARTIES MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY REGARDING THE ADVISABILITY OF INVESTING IN FUNDS GENERALLY OR IN THESE FUNDS PARTICULARLY OR THE ABILITY OF ANY MSCI INDEX TO TRACK CORRESPONDING STOCK MARKET PERFORMANCE. MSCI OR ITS AFFILIATES ARE THE LICENSORS OF CERTAIN TRADEMARKS, SERVICE MARKS AND TRADE NAMES AND OF THE MSCI INDEXES WHICH ARE DETERMINED, COMPOSED AND CALCULATED BY MSCI WITHOUT REGARD TO THESE FUNDS OR THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY. NONE OF THE MSCI PARTIES HAS ANY OBLIGATION TO TAKE THE NEEDS OF THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY INTO CONSIDERATION IN DETERMINING, COMPOSING OR CALCULATING THE MSCI INDEXES. NONE OF THE MSCI PARTIES IS RESPONSIBLE FOR OR HAS PARTICIPATED IN THE DETERMINATION OF THE TIMING OF, PRICES AT, OR QUANTITIES OF THESE FUNDS TO BE ISSUED OR IN THE DETERMINATION OR CALCULATION OF THE EQUATION BY OR THE CONSIDERATION INTO WHICH THESE FUNDS ARE REDEEMABLE. FURTHER, NONE OF THE MSCI PARTIES HAS ANY OBLIGATION OR LIABILITY TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY IN CONNECTION WITH THE ADMINISTRATION,

MARKETING OR OFFERING OF MSCI Genomic Healthcare Innovation UCITS ETF.

ALTHOUGH MSCI SHALL OBTAIN INFORMATION FOR INCLUSION IN OR FOR USE IN THE CALCULATION OF THE MSCI INDEXES FROM SOURCES THAT MSCI CONSIDERS RELIABLE, NONE OF THE MSCI PARTIES WARRANTS OR GUARANTEES THE ORIGINALITY, ACCURACY AND/OR THE COMPLETENESS OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY THE ISSUER OF THE FUNDS, OWNERS OF THE FUNDS, OR ANY OTHER PERSON OR ENTITY, FROM THE USE OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES SHALL HAVE ANY LIABILITY FOR ANY ERRORS, OMISSIONS OR INTERRUPTIONS OF OR IN CONNECTION WITH ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. FURTHER, NONE OF THE MSCI PARTIES MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF ANY KIND, AND THE MSCI PARTIES HEREBY EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO EACH MSCI INDEX AND ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL ANY OF THE MSCI PARTIES HAVE ANY LIABILITY FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR ANY OTHER DAMAGES (INCLUDING LOST PROFITS) EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

No purchaser, seller or holder of this security, product or Funds, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this security without first contacting MSCI to determine whether MSCI's permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI.

